306 related articles for article (PubMed ID: 12971972)
1. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
Teuber G; Pascu M; Berg T; Lafrenz M; Pausch J; Kullmann F; Ramadori G; Arnold R; Weidenbach H; Musch E; Junge U; Wiedmann KH; Herrmann E; Zankel M; Zeuzem S
J Hepatol; 2003 Oct; 39(4):606-13. PubMed ID: 12971972
[TBL] [Abstract][Full Text] [Related]
2. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
Engler S; Flechtenmacher C; Wiedemann KH; Gugler R; Stremmel W; Kallinowski B
J Viral Hepat; 2004 Jan; 11(1):60-8. PubMed ID: 14738559
[TBL] [Abstract][Full Text] [Related]
3. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
Berg T; Kronenberger B; Hinrichsen H; Gerlach T; Buggisch P; Herrmann E; Spengler U; Goeser T; Nasser S; Wursthorn K; Pape GR; Hopf U; Zeuzem S
Hepatology; 2003 Jun; 37(6):1359-67. PubMed ID: 12774015
[TBL] [Abstract][Full Text] [Related]
4. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
Berg T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2001 Feb; 39(2):145-51. PubMed ID: 11253505
[TBL] [Abstract][Full Text] [Related]
6. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study.
Weegink CJ; Sentjens RE; Beld MG; Dijkgraaf MG; Reesink HW
J Viral Hepat; 2003 May; 10(3):174-82. PubMed ID: 12753335
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
Younossi ZM; Mullen KD; Zakko W; Hodnick S; Brand E; Barnes DS; Carey WD; McCullough AC; Easley K; Boparai N; Gramlich T
J Hepatol; 2001 Jan; 34(1):128-33. PubMed ID: 11211889
[TBL] [Abstract][Full Text] [Related]
10. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
11. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
Thuluvath PJ; Maheshwari A; Mehdi J; Fairbanks KD; Wu LL; Gelrud LG; Ryan MJ; Anania FA; Lobis IF; Black M
Gut; 2004 Jan; 53(1):130-5. PubMed ID: 14684587
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
[TBL] [Abstract][Full Text] [Related]
13. Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C.
Younossi ZM; Mullen KD; Hodnick S; Barnes DS; Carey WD; McCullough AC; Easley K; Gramlich T; Liebermann BY
J Clin Gastroenterol; 2003; 36(5):427-30. PubMed ID: 12702987
[TBL] [Abstract][Full Text] [Related]
14. High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients--results of a randomized, prospective, pilot study.
Ullerich H; Avenhaus W; Poremba C; Domschke W; Menzel J
Aliment Pharmacol Ther; 2002 Dec; 16(12):2107-14. PubMed ID: 12452944
[TBL] [Abstract][Full Text] [Related]
15. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Rizzo G; Barbarini G
Am J Gastroenterol; 1998 Dec; 93(12):2445-51. PubMed ID: 9860407
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.
Herrine SK; Brown RS; Bernstein DE; Ondovik MS; Lentz E; Te H
Dig Dis Sci; 2005 Apr; 50(4):719-26. PubMed ID: 15844708
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.
Puoti M; Zanini B; Quinzan GP; Ravasio L; Paraninfo G; Santantonio T; Rollo A; Artioli S; Maggiolo F; Zaltron S; Raise E; Mignani E; Resta F; Verucchi G; Pastore G; Suter F; Carosi G;
J Hepatol; 2004 Aug; 41(2):312-8. PubMed ID: 15288482
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.
Tassopoulos NC; Tsantoulas D; Raptopoulou M; Vassiliadis T; Kanatakis S; Paraskevas E; Vafiadis I; Avgerinos A; Tzathas C; Manolakopoulos S; Ketikoglou I; Aggelis P; Goritsas K; Giannoulis G; Hatzis G G; Thomopoulos K; Akriviadis E; Sypsa V; Hatzakis A
J Viral Hepat; 2003 May; 10(3):189-96. PubMed ID: 12753337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
